Eli Lilly › Eli Lilly (NYSE: LLY) has been a terrific stock to own over the past 15 years; it has consistently outperformed ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its stock bounce back a modest 2.5% through 1:55 p.m. ET Monday on some ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Shares of Eli Lilly (LLY) are testing a resistance level. If they can break through this resistance, a large more higher may follow.

Eli Lilly's GLP-1 drugs fuel massive growth, with potential $60bn+ annual revenue. Check out why I remain bullish long term on LLY stock.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly stock dropped more than 20% due to underwhelming results from its drug trials. However, a rebound may be underway.

Eli Lilly (LLY) announced positive results from the Phase 3 MonarchE and ATTAIN-2 trials, signaling significant advancements ...

The bear case for Eli Lilly has now played out following the reaction to the drugmaker’s oral obesity drug trial, an analyst ...

Shares of Eli Lilly ( LLY -2.30%) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for ...